Medicine and Dentistry
25 Hydroxyvitamin D
14%
Adolescent
14%
Alfacalcidol
10%
Bone Density
13%
Bone Mineral
14%
Bone Strength
9%
Burosumab
30%
Child
9%
Chronic Disease
20%
Cohort Analysis
20%
Combination Therapy
33%
Cross Sectional Study
10%
Denosumab
19%
Disease
28%
Epileptic Seizure
12%
Fetus Lung Maturation
9%
Fibroblast Growth Factor 23
16%
First Trimester Pregnancy
9%
Hypophosphatemic Rickets
51%
Hypovitaminosis D
15%
Interim Analysis
19%
Leg
15%
Lung Dysplasia
9%
Medical Record
11%
Mental Health
10%
Observational Study
13%
Osteoclast Differentiation Factor
9%
Osteoclastoma
9%
Osteogenesis Imperfecta
9%
Oxygen Saturation
9%
Oxygenase
9%
Pediatrics
17%
Prevalence
33%
Pycnodysostosis
9%
Quality of Life
22%
Randomized Controlled Trial
15%
Rickets
48%
Sacrum
9%
Spontaneous Abortion
9%
Surgery
9%
Survival Time
9%
Symptom
10%
Systematic Review
20%
Thyroid Disease
10%
Tricho-Rhino-Phalangeal Syndrome
9%
Vitamin D
56%
Vitamin D Deficiency
11%
Von Hippel-Lindau Disease
9%
X Linked Hypophosphatemic Rickets
100%
Zoledronic Acid
9%
Pharmacology, Toxicology and Pharmaceutical Science
25 Hydroxyvitamin D
12%
Alfacalcidol
8%
Burosumab
19%
Chronic Disease
9%
Cohort Study
20%
Combination Therapy
22%
Denosumab
19%
Disease
19%
Graves Disease
8%
Hashimoto Disease
7%
Hypophosphatemic Rickets
30%
Hypovitaminosis D
22%
Inflammatory Bowel Disease
9%
Lung Dysplasia
9%
Neoplasm
6%
Osteoclast Differentiation Factor
9%
Osteoclastoma
9%
Oxygenase
9%
Prevalence
19%
Randomized Controlled Trial
11%
Respiratory Distress Syndrome
8%
Rickets
36%
Side Effect
6%
Surfactant
6%
Survival Time
9%
Symptom
5%
Tablet
9%
Thyroid Disease
9%
Vitamin D
55%
Vitamin D Deficiency
9%
X-Linked Hypophosphatemia
29%
Zoledronic Acid
9%
Biochemistry, Genetics and Molecular Biology
Body Weight
9%
Bone Development
9%
Bone Remodeling
9%
CLCN5
9%
Cohort Study
9%
Craniofacial Morphology
9%
Fibroblast Growth Factor 23
10%
Genetics
19%
Hypovitaminosis D
11%
Leg Length
9%
Lung Weight
9%
Oxygen Saturation
9%
Oxygenase
9%
Prevalence
5%
Progeny
9%
Rickets
13%
Sclerostin
9%
Survival Time
9%
Tricho-Rhino-Phalangeal Syndrome Type 1
9%
Vitamin D
24%
X-Linked Hypophosphatemia
48%